Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age.

Lindsey, Jane C; Jacobson, Denise L; Spiegel, Hans M; Gordon, Catherine M; Hazra, Rohan; Siberry, George K

Lindsey, Jane C; Jacobson, Denise L; Spiegel, Hans M; Gordon, Catherine M; Hazra, Rohan; Siberry, George K.

Afiliação

Lindsey JC; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Jacobson DL; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Spiegel HM; Kelly Government Solutions, Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland, USA.
Gordon CM; Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Hazra R; Maternal and Pediatric Infectious Diseases Branch, Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
Siberry GK; Office of HIV/AIDS, US Agency for International Development, Washington, D.C., USA.

Clin Infect Dis ; 72(6): 1059-1063, 2021 03 15.

Article em En | MEDLINE | ID: mdl-32584996

ABSTRACT

ABSTRACT

No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.

Assuntos

Conservadores da Densidade Óssea; Doenças Ósseas Metabólicas; Infecções por HIV; Adolescente; Alendronato/efeitos adversos; Densidade Óssea; Criança; Estudos Cross-Over; Infecções por HIV/complicações; Infecções por HIV/tratamento farmacológico; Humanos

Palavras-chave

HIV infection; bisphosphonates; bone; children

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Ósseas Metabólicas / Infecções por HIV / Conservadores da Densidade Óssea Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google